Thirty-Eighth Board Meeting

Show entries

Search:

Date YYYY-MM-DD	Board Meeting	Decision Point Number	Title
2018-04-26	B38	GF/B38/EDP18	Key Performance Indicator 12b: Availability of affordable health technologies: Affordability Key Performance Indicator 12b: Availability of affordable health technologies: Affordability <p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves the 2018 performance target for Key Performance Indicator 12b as presented in GF/B38/ER13A.</p>
2018-04-11	B38	GF/B38/EDP17	Decision on the Secretariat’s Recommendation on Additional Funding Decision on the Secretariat’s Recommendation on Additional Funding <p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B38/EDP17 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the revised budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding. </li> </ol>
2018-04-11	B38	GF/B38/EDP16	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B38/EDP16 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b,or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>
2018-03-23	B38	GF/B38/EDP15	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP15 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-03-13	B38	GF/B38/EDP14	Appointment of new Member to the Global Fund Strategy Committee Appointment of new Member to the Global Fund Strategy Committee <ol> <li>The Board approves the appointment of Madame Estelle Tiphonnet-Diawara, representing the French Constituency, as a voting member of the Strategy Committee (“SC”) for a term that will expire in May 2018, or until the appointment of her successor.</li> </ol>
2018-03-08	B38	GF/B38/EDP13	Approval of the Global Fund Honorarium Framework Approval of the Global Fund Honorarium Framework <p>Approves the Global Fund Honorarium Framework, as set forth in Annex 1 to GF/B38/ER09.</p>
2018-02-23	B38	GF/B38/EDP12	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP12 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-02-16	B38	GF/B38/EDP11	Location of the 39th Board Meeting Location of the 39th Board Meeting <ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of the Former Yugoslav Republic of Macedonia to host the Global Fund’s 39th Board Meeting on 9-10 May 2018; and</li> <li>Acknowledges the recommendation set forth in GF/B38/ER07. </li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board agrees to convene the 39th Board Meeting in Skopje, Former Yugoslav Republic of Macedonia.</li> </ol>
2018-01-23	B38	GF/B38/EDP10	Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board Appointment of the Chairs and Vice-Chairs of the Standing Committees of the Board <ol> <li>The Board approves the appointment of: <ol type="i"> <li>Beatrijs Stikkers-Muller as Chair of the Audit and Finance Committee;</li> <li>Anthony Garnett as Vice-Chair of the Audit and Finance Committee;</li> <li>Sandra Thurman as Chair of the Ethics and Governance Committee;</li> <li>Grace Rwakarema as Vice-Chair of the Ethics and Governance Committee;</li> <li>Kieran Daly as Chair of the Strategy Committee; and</li> <li>Abdalla Osman as Vice-Chair of the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 11 May 2018 and serve for two years or until the appointment of their successor.</li> </ol>
2018-01-12	B38	GF/B38/EDP09	Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions <p>Set forth below is the Secretariat’s recommendation to approve grant extensions. </p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/EDP09 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2018-01-12	B38	GF/B38/EDP08	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to <span>GF/B38/EDP08</span> (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2018-01-12	B38	GF/B38/EDP07	Report of the 38th Board Meeting Report of the 38th Board Meeting <p>Report of the 38th Board Meeting</p>
2017-12-15	B38	GF/B38/EDP06	Approval of Guideline for Annual Performance Assessment of Board Direct Reports Approval of Guideline for Annual Performance Assessment of Board Direct Reports <p>The Board:</p> <ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Guideline for Annual Performance Assessment of Board Direct Reports as set forth in Annex 1 to GF/B38/ER04. This Guideline shall apply to the assessment of the performance of the Executive Director and the Inspector General during 2018 and onward.</li> <li>The Board directs the Ethics and Governance Committee (EGC) to review the guideline every three years, starting in 2020, to ensure its continued relevance.</li> <li>The Board delegates to the EGC the authority to approve revisions to the Guideline for Annual Performance Assessment to Board Direct Reports and to report such changes to the Board.</li> <li>The Board delegates to the EGC the authority to appoint a member of the EGC in replacement of the Board Chair or Vice Chair for the purposes of the performance assessment of the Executive Director or Inspector General in the event of a recusal of any of the said officials.</li> </ol>
2017-12-13	B38	GF/B38/EDP05	Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions <p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/ER05 (“Table 2”);</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.</li> </ol>
2017-12-13	B38	GF/B38/EDP04	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <p>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 1,321,996,861 and EUR 52,050,991; this includes country allocation funding as well as US$ 32,737,727 of catalytic investments for matching funds.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-12-01	B38	GF/B38/EDP03	Decision on the Secretariat’s Recommendation on Grant Extensions Decision on the Secretariat’s Recommendation on Grant Extensions <p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of GF/B38/ER02 (“Table 2”);</li> </ol>
2017-12-01	B38	GF/B38/EDP02	Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation <ul> <li>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,317,504,873 and EUR 434,148,572; this includes country allocation funding as well as US$46,519,790 and EUR 1,782,000 of catalytic investments for matching funds.</li> </ul> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>
2017-11-30	B38	GF/B38/EDP01	Principles of the LFA Procurement Method Principles of the LFA Procurement Method <p>The Board, taking into account the specific nature of Local Fund Agent (the “LFA”) services as described in GF/B38/ER01 decides to:</p> <ol> <li>Replace its prior decision on Re-tendering Local Fund Agent Contracts (GF/B15/DP50) with the Principles of the LFA Procurement Method: Differentiation; Ensuring value-for-money through monitoring LFA performance and cost; Encouraging the diversity of LFA service providers; and Unique contracting arrangements, as set forth in Part 6 of GF/B38/EDP01 (the “Principles of the LFA Procurement Method”);</li> <li>Delegate to the AFC the authority to approve modifications to the Principles of the LFA Procurement Method; and</li> <li>Delegate to the Secretariat the authority to approve the procedures for procurement of LFA services in accordance with the Principles of the LFA Procurement Method Budgetary implications: no additional resources required</li> </ol>
2017-11-15	B38	GF/B38/DP09	Approval of Policy to Combat Fraud and Corruption Approval of Policy to Combat Fraud and Corruption <ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Global Fund Policy to Combat Fraud and Corruption as set forth in Annex 4 to GF/B38/06 – Revision 2;</li> <li>The Board directs the Executive Director to develop an implementation plan, and to periodically report to the Board through the Ethics and Governance Committee on its implementation of the Policy to Combat Fraud and Corruption, as part of regular updates pursuant to the Ethics and Integrity Framework; </li> <li>Consistent with his/her authority to implement the Policy to Combat Fraud and Corruption, the Executive Director shall have delegated authority to approve exceptions to the Policy. This provision does not apply to access rights of the Office of the Inspector General for which the Inspector General shall have such delegated authority; and</li> <li>The Board further directs that appropriate and regular reporting be made by the Executive Director and Inspector General to the Ethics and Governance Committee or the Audit and Finance Committee on the exercise of the authority delegated under paragraph 3 of this Decision Point; and</li> <li>The authority delegated to the Executive Director and the Inspector General, as the case may be, under paragraph 3 of this Decision Point expires at the moment when the Board has adopted the framework the Board has requested the Secretariat to develop in GF/B37/DP07.</li> </ol>
2017-11-15	B38	GF/B38/DP08	Targets for Key Performance Indicators 3, 6a, 6b, 6e and 12b Targets for Key Performance Indicators 3, 6a, 6b, 6e and 12b <ol> <li>Based on the recommendation of the Audit and Finance Committee contained in GF/AFC05/DP01, the Board approves the 2018 performance target for Key<br />Performance Indicator 12b as presented in GF/B38/05A and notes the review of the 2018 target planned for Q1 2018.</li> <li>Based on the recommendation of the Strategy Committee contained in GF/SC05/DP04, the Board: <ol type="a"> <li>Approves the performance targets for Key Performance Indicators 3, 6a i, 6a ii, 6b and 6e as presented in GF/B38/05A; and</li> <li>Agrees to postpone its review and approval of the performance target for Key Performance Indicator 6a iii, until such time as a baseline is available.</li> </ol> </li> </ol>

Showing 1 to 20 of 27 entries